Biopharma Co. Adds CTO to Team

Research Report
  ()
This newest member brings with him extensive experience in protein development and manufacturing, noted an Oppenheimer report.

Trial Results Validate New Drug-Delivering Nasal Implant

Research Report
  ()
This product candidate presents a compelling approach to treating post-surgery chronic rhinosinusitis patients, noted an H.C. Wainwright & Co. report.

Biotech Co. Makes Strides on Three Fronts

Research Report
  ()
This Canadian firm sold assets, launched an equity raise and filed a clinical trial application for its lead psychedelic-assisted psychotherapy program, noted a Stifel report.
Tags:  Psychedelics

Telehealth Co. Signs Contract With Client in Eight States

  ()
This telehealth company has signed a new contract for its remote patient monitoring platform to be used by a leading healthcare company with dozens of locations in eight states.

Telehealth Co. Expands Platform To Cover Pediatric Patients

  ()
This telehealth company is expanding its platform to cover remote monitoring for pediatric patients with diabetes and other eligible conditions. Find out why one analyst says this company's stock is gathering momentum.

Co. Reaches Major Milestone With Novel Drug

Research Report
  ()
The biopharma initiated enrollment of a targeted 420 patients for one of its Phase 3 clinical trials evaluating its new cardiac myosin inhibitor, noted an H.C. Wainwright & Co. report.

Cryoablation System Gets Approved in Brazil

Research Report
  ()
The product developer expects to generate US$6.6 million in sales of this medical device in Brazil over the next five years, noted an H.C. Wainwright & Co. report.

FTC Settles Suit, Potentially Averting Further Hurdles

Contributed Opinion
  ()
McAlinden Research shares a deep dive into a market driver with alpha-generating potential.

After Seeing 86% Success Rate in Phase 2, Biotech Co. Moves to Phase 3 for AUD Treatment

  ()
Awakn Life Sciences has applied for Phase 3 of clinical trials after the success of Phase 2. Read on to see what this company plans for its flagship new drug.

Contract Adding Thousands of Patients to Co.'s Telehealth Platform

  ()
This telehealth company has signed a new contract with a Texas respiratory clinic that is expected to add 10,000 new patients to its iUGO platform by mid-2024. Read to see why one analyst believes this stock is a Buy.

Approved Drug for Skin Condition Shown Safe at Higher Dose

Research Report
  ()
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.

New Vaccine for Chikungunya Shown To Be Safe in Youths

Research Report
  ()
The company behind the vaccine plans to use the safety data to support approvals in the U.S., European Union and Brazil, noted an H.C. Wainwright & Co. report.

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023

  ()
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.

DNA Tech Co. Launches MRNA Platform and Files Two Patents

  ()
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.

Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.

Research Report
  ()
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.

FDA Approves New Oncology Drug for Clinical Trials

Research Report
  ()
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report.

Expert Investing Ideas

"Positive Phase 2a data were achieved with AGN's ifenprodil."

–Dr. André Uddin, Research Capital Corporation


"AGN is rated a Buy again here."

–Clive Maund, CliveMaund.com


"AGN is rated an immediate Strong Buy."

–Clive Maund, CliveMaund.com


"AGN is rated Buy again here."

–Clive Maund, CliveMaund.com


"AGN has the capacity to make really big moves."

–Clive Maund, CliveMaund.com


"It would be logical for AGN to develop ifenprodil for two indications."

–Dr. André Uddin, Research Capital Corporation


"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

–Dr. André Uddin, Research Capital Corporation


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Telehealth Co. Launches Monitoring Program for Acute Patients

  ()
Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico.

Co. Still Undervalued Post Solid Q2/23

Research Report
  ()
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report.
Tags:  Cannabis

Med Tech Firm's Q2/23 Revenue Beats Target

Research Report
  ()
The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report.

Telehealth Co. Inks Contracts With Rural Clinics in 5 States, Territories

  ()
Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands.

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside

Contributed Opinion
  ()
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short.